Commenting, John Brown (chairman), said “Synpromics is a very exciting company working in the highly dynamic synthetic biology industry. The investment recognises the fantastic work of the science team in successfully achieving its technical objectives for all of our projects whilst the business development pipeline has developed significantly, based on the technical success to date. We have a great team and welcome calculus to the company.”
David Venables (CEO) added “we are extremely pleased to have attracted this investment from a leading eis fund that has strong technology expertise. The work done by Michael Roberts (CSO and founder) and his team has evidenced the robustness of the technology and its wide applicability across gene therapy, agroscience, bioprocessing including yeast and mammalian cells. We now plan to focus our growth efforts in particular areas leveraging the great results from our projects. Recent data from a project in cho cells showed a ten fold improvement in yield using custom made promoters whilst other projects have shown that we can achieve highly specific levels of control over gene expression. These results make us a compelling partner for many biotech and synthetic biology businesses. We look forward to building the business with calculus.”
Alexandra Lindsay (Calculus) added “We are very excited to invest in Synpromics. The highly capable team, comprehensive IP and leading technology, together with Calculus Capital’s support, will ensure Synpromics is primed to take full advantage of the significant market opportunity available."
Calculus Capital is a specialist in creating and managing private equity funds for individuals. A pioneer in the enterprise investment scheme (EIS) space, calculus launched the UK’s first approved EIS fund in 1999 and has gone on to launch 15 further funds. Calculus seeks capital appreciation from dynamic, established, private UK companies across a multitude of sectors, calculus prefers to invest £2m - £5m per company.